首页> 外文OA文献 >TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

【2h】

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

机译：TAS6417 / CLN-081是一种泛突变选择性EGFR酪氨酸激酶抑制剂，具有较广泛的临床相关EGFR突变的临床前活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hibiki Udagawa; Shinichi Hasako; Akihiro Ohashi; Rumi Fujioka; Yumi Hakozaki; Mikiko Shibuya; Naomi Abe; Toshiharu Komori; Tomonori Haruma; Miki Terasaka; Ryoto Fujita; Akihiro Hashimoto; Kaoru Funabashi; Hiroyuki Yasuda; Kazutaka Miyadera; Koichi Goto; Daniel B. Costa; Susumu S. Kobayashi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. 第一代酪氨酸激酶抑制剂治疗中发生进展的非小细胞肺癌血浆表皮生长因子受体(EGFR) T790M突变提示了失败部位并预测了临床预后:一项前瞻性观察研究 [J] . Shirong Zhang, Lucheng Zhu, Bing Xia, 癌症（英文版） . 2018,第009期
3. TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations [J] . Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Molecular cancer research: MCR . 2019,第11期

机译：TAS6417 / CLN-081是一种泛突变选择性EGFR酪氨酸激酶抑制剂，具有临床相关EGFR突变的广谱临床前活性
4. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis [J] . Lee Chee Khoon, Wu Yi-Long, Ding Pei Ni, Journal of Clinical Oncology . 2015,第17期

机译：表皮生长因子受体（EGFR）突变和临床特征对EGFR突变型肺癌患者EGFR酪氨酸激酶抑制剂与化学疗法治疗结果的影响：一项荟萃分析
5. Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene. [J] . Rizvi NA, Rusch V, Pao W, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第10期

机译：分子特征预测临床结果：对EGFR酪氨酸激酶抑制剂吉非替尼的前瞻性试验相关反应，并在EGFR基因酪氨酸结合域中存在敏化突变。
6. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma [C] . Yeul Hong Kim, Hye Sook Kim, Jae Sook Sung, Molecular Medicine TRI-CON. . 2014

机译：下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
7. Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer. [D] . Zhou, Yunfei. 2005

机译：小分子酪氨酸激酶抑制剂在人结肠癌中靶向EGFR和ErbB2。
8. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer [O] . Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, 2015

机译：在非小细胞肺癌中体外建模以确定EGFR酪氨酸激酶抑制剂对临床相关EGFR突变体的突变特异性
9. P2-066: Analysis of EGFR gene copy number, EGFR mutations, KRAS mutations and EGFR expression in a cohort of non-small cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors at a North American institution. [O] . Box Alan K., Otsuka Shannon, Morris Don, 2007

机译：P2-066：在北美一家机构中对使用表皮生长因子酪氨酸激酶抑制剂治疗的非小细胞肺癌患者队列中的EGFR基因拷贝数，EGFR突变，KRAS突变和EGFR表达进行了分析。

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

著录项

引文网络

相似文献

相关主题

期刊订阅